---
title: Draupnir Bio
date: 2019-04-10T07:46:50Z
modified: 2026-08-11T09:54:04Z
permalink: "https://www.htgf.de/en/portfolio/htgffamily/draupnir-bio/"
type: portfolio
status: publish
excerpt: ""
wpid: 71029
language:
  - English
post_translations:
  - pll_5cad9f5216d51
branchen22:
  - Cardiology / Cardiovascular
sectors:
  - Pharmaceuticals
focus_areas:
  - Cardiology
timestamp: 2026-08-11T09:54:04Z
tags:
  - English
  - pll_5cad9f5216d51
  - Cardiology / Cardiovascular
  - Pharmaceuticals
  - Cardiology
---

## Beschreibungstext

Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society and establishing itself at the forefront of protein degradation. Draupnir’s novel and proprietary platform technology is enabling the development of protein degraders that target extracellular disease proteins, with potential to target 40% of the human proteome and offering broad disease applicability across multiple areas. Through this differentiated platform technology, it’s building a broad pipeline of oral small molecule degraders of extracellular pathogenic proteins.

## Unternehmenswebsite

https://draupnir.bio/

## Adresse

Draupnir Bio ApS 
CVR no. 38 54 68 80
Solsikkevej 8 
8240 Risskov
Denmark

## Kontakt

Array